|
Market Closed -
Nasdaq
16:00:00 2026-08-21 EDT
|
5-day change | 1st Jan Change | ||
| 13.33 USD | -3.55% |
|
+0.30% | +93.19% |
| 08-06 | B. Riley Adjusts COMPASS Pathways Price Target to $22 From $17, Maintains Buy Rating | MT |
| 08-06 | RBC Adjusts PT on COMPASS Pathways to $21 From $22, Maintains Outperform Speculative Risk Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| COMPASS PATHWAYS PLC | Other Biotechnology & Medical Research | -3.55% | +0.30% | +93.19% | +226.72% | -56.52% | 1.91B |  | | |
- Stock Market
- Stocks
- CMPS Stock
- Charts COMPASS Pathways plc
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
